Department of Urology, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510700, China.
Department of Hospital Infection Control, Huangpu District Hospital of Traditional Chinese Medicine, Guangzhou, 510799, China.
BMC Urol. 2024 Oct 5;24(1):214. doi: 10.1186/s12894-024-01609-2.
The effectiveness of metallic stents in treating ureteral strictures following surgery and radiotherapy for gynecological tumors is currently uncertain. We aimed to investigate the efficacy and safety of thermo-expandable metallic stent (Memokath) in the treatment of ureteral stricture after radiotherapy for gynecological tumors.
In this descriptive cross-sectional study, 27 patients with ureteral stricture were treated with Memokath stent after gynecological tumor radiotherapy with or without chemotherapy that was admitted to our hospital from August 2021 to August 2023. Clinical data on efficacy, safety, and complications during stent insertion and indwelling were analyzed.
The successful insertion of thirty-three stents in twenty-seven patients studied. The stenosis length was 10.14 ± 6.76 cm, and the hospitalization was 4.43 ± 1.83 days. One patient has died from the primary disease carrying a patency stent. The Kaplan-Meier graph showed that the cumilative patency rate of patients with thermo-expandable metallic stent were 92.4% (SD = 5.2%) in eight months, 77.4% (9.1%) in 12 months and 67.7% (SD = 12%) in 29 months, while the cumilative survival rate was 87.5% (SD = 11.5%) in 29 months. The stent patency was 81.48% and later complications of stent indwelling were 5/27, including refractory urinary tract infection (UTI) in three cases, stent migration, and stent intolerance respectively. The creatinine levels, hydronephrosis degree, and glomerular filtration rate improved after the operation, and the first two indicators were statistically significant.
Memokath stent is a safe and effective treatment for ureteral stricture after surgery and radiotherapy with or without chemotherapy for gynecological tumors.
金属支架治疗妇科肿瘤术后放疗后输尿管狭窄的效果尚不确定。本研究旨在探讨热膨胀型金属支架（Memokath）治疗妇科肿瘤放疗后输尿管狭窄的疗效和安全性。
本研究为描述性横断面研究，纳入 2021 年 8 月至 2023 年 8 月因妇科肿瘤接受放化疗或单纯放疗后发生输尿管狭窄并接受 Memokath 支架置入的 27 例患者。分析支架置入和留置期间的疗效、安全性及并发症相关的临床资料。
27 例患者共成功置入 33 枚支架，狭窄段长度为 10.14±6.76 cm，住院时间为 4.43±1.83 天。1 例患者因原发疾病死亡，携带通畅支架。Kaplan-Meier 曲线显示，8 个月、12 个月和 29 个月时，热膨胀型金属支架患者的累积通畅率分别为 92.4%（SD=5.2%）、77.4%（9.1%）和 67.7%（SD=12%），29 个月时的累积生存率为 87.5%（SD=11.5%）。支架通畅率为 81.48%，支架留置后出现的并发症有 5/27 例，包括难治性尿路感染（UTI）3 例、支架移位和支架不耐受各 1 例。术后患者的肌酐水平、肾积水程度和肾小球滤过率均得到改善，前两项指标有统计学意义。
Memokath 支架治疗妇科肿瘤术后放疗后输尿管狭窄安全有效。
